Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: Ten years of successful antivascular therapy

被引：20
作者：
Alexander M. M. Eggermont
Timo L. M. ten Hagen
机构：
[1] Erasmus University Medical Center,Department of Surgical Oncology
[2] Daniel den Hoed Cancer Center,undefined
来源：
Current Oncology Reports | 2003年 / 5卷 / 2期
关键词：
Tumor Necrosis Factor; Soft Tissue Sarcoma; Limb Salvage; Isolate Limb Perfusion; Isolate Hepatic Perfusion;
D O I：
10.1007/s11912-003-0091-x
中图分类号：
学科分类号：
摘要：
TNF-based ILP is very successful as a treatment to achieve limb salvage in the management of advanced, multiple, or drug-resistant extremity tumors. TNF-based ILP is now performed in 30 cancer centers in Europe. TNF-based antivascular therapy for cancer is here to stay, and its potential needs to be studied further [7].
引用
收藏
页码：79 / 80
页数：1
相关论文
共 21 条
[1]  
Lienard D(1992)High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J Clin Oncol 10 50-62
[2]  
Ewalenko P(1996)Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience Ann Surg 224 756-765
[3]  
Delmotte JJ(2000)Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br J Cancer 82 1000-1003
[4]  
Eggermont AMM(1998)Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFNgamma Nat Med 4 408-414
[5]  
Schraffordt Koops H(1998)Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver J Clin Oncol 16 1479-1489
[6]  
Klausner JM(2000)Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats Int J Cancer 87 829-837
[7]  
De Wilt JHW(2001)TNF is here to stay—revisited Trends Immunol 22 127-129
[8]  
ten Hagen TLM(undefined)undefined undefined undefined undefined-undefined
[9]  
de Boeck G(undefined)undefined undefined undefined undefined-undefined
[10]  
Ruegg C(undefined)undefined undefined undefined undefined-undefined
123